Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00252291

Recruitment Status : Completed

First Posted : November 11, 2005

Last Update Posted : December 1, 2009

Sponsor:

Information provided by:

Pharmaxis

Study Description

Brief Summary:

This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 >70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.

Condition or disease	Intervention/treatment	Phase
Asthma	Drug: Aridol Drug: Methacholine Procedure: Exercise challenge	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	240 participants
Allocation:	Randomized
Intervention Model:	Crossover Assignment
Masking:	Single
Primary Purpose:	Diagnostic
Official Title:	A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting With Signs and Symptoms Suggestive of Asthma But Without a Definitive Diagnosis
Study Start Date :	November 2005
Actual Study Completion Date :	September 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma Exercise and Physical Fitness

Drug Information available for: Mannitol

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

Comparison of Aridol and exercise BHR tests
Safety of Aridol test

Secondary Outcome Measures :

Comparison of Aridol and methacholine test
Comparison of Aridol test and clinical diagnosis

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	6 Years to 50 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Have given informed consent to participate in this study in accordance with local regulations prior to any procedures being performed
Have signs and symptoms suggestive of asthma according to the NIH Questionnaire but has not been given a firm diagnosis of asthma or a firm exclusion of the diagnosis of asthma (e.g. has an equivocal diagnosis of asthma or been referred for further investigation of asthma type symptoms)
Have at least Step 1 symptoms according to the NAEPPII asthma severity grading
Have an FEV1 ≥ 70% of the predicted value at Screening Visit (Visit 1) baseline
Be between 6 and 50 years
Be able to perform all of the techniques necessary to measure lung function including an exercise challenge, Aridol challenge and methacholine challenge
Be able to understand the requirements of the study and be able to complete all of the forms necessary including the NIH Questionnaire
Be taking effective birth control if female of childbearing potential

Exclusion Criteria:

Use medications six weeks prior to the Screening Visit (Visit 1) or during the study that would interfere with bronchial provocation challenge testing (see Table 1, section 3.3.3.4)
Currently use cholinesterase-inhibitor medication (for myasthenia gravis)
Have had upper or lower respiratory tract infection within the previous 4 weeks
Have known aortic or cerebral aneurysm, cirrhosis or portal hypertension
Have had recent major surgery
Have had recent cataract surgery
Have a history of heart disease that would increase risk of performing exercise, methacholine or Aridol challenge
Have had cardiac ischemia or malignant arrhythmias
Have uncontrolled hypertension (systolic blood pressure ≥ 180 and diastolic blood pressure ≥ 100)
Have orthopedic limitations
Have smoked within the past year (average > 1 cigarette per week), or have a ≥ 10 pack year smoking history
Have other chronic restrictive or obstructive pulmonary diseases (cystic fibrosis, COPD, bronchiectasis, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension, hypercapnia)
Be skin test positive to seasonal and perennial aeroallergens that are present in the environment during the time that the subject is enrolled in the study, or if skin test positive to these aeroallergens the subject must not report worsening of symptoms when exposed to these aeroallergens during the time that the subject is participating in the study
Have a medical condition that in the opinion of the Investigator would impair the ability of the subject to participate
Have an inability to perform spirometry of acceptable quality
Be intolerant to Aridol, methacholine or albuterol
Be pregnant or lactating
Have participated in any other investigative drug study parallel to, or within 4 weeks of study entry
Be an Investigator, site employee or otherwise be directly affiliated with the study site including being a member of the immediate family of an Investigator, site employee (where an immediate family member is defined as spouse, parent, child or sibling, whether biological or legally adopted or in foster care)
Have a body mass index (BMI) ≥ 30
Have been diagnosed at Screening Visit (Visit 1) as definitively having or not having asthma; patients that will not continue in the study include those given the following diagnosis: asthma is extremely likely or definite (95 to 100% likelihood) or asthma is very unlikely or excluded (0 to < 5% likelihood)
Have previously been enrolled in this study at this or at any other clinical trials site
Have previously received an Aridol challenge
Have a clinically significantly abnormal chest x-ray

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00252291

Locations


United States, Colorado
Colorado Asthma and Allergy Centers, 125 Rampart Way
Denver, Colorado, United States, 80230-6405

Sponsors and Collaborators

Pharmaxis

Investigators


Principal Investigator:	David Pearlman, MD	Colorado Asthma and Allergy Centers, Denver, CO

More Information

Publications:

Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, Gonda I, Walsh A, Clark AR. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):758-65.

Subbarao P, Brannan JD, Ho B, Anderson SD, Chan HK, Coates AL. Inhaled mannitol identifies methacholine-responsive children with active asthma. Pediatr Pulmonol. 2000 Apr;29(4):291-8.

Holzer K, Anderson SD, Chan HK, Douglass J. Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med. 2003 Feb 15;167(4):534-7. Epub 2002 Nov 27.

Koskela HO, Hyvärinen L, Brannan JD, Chan HK, Anderson SD. Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest. 2003 Oct;124(4):1341-9.


ClinicalTrials.gov Identifier:	NCT00252291 History of Changes
Other Study ID Numbers:	DPM-A-305
First Posted:	November 11, 2005 Key Record Dates
Last Update Posted:	December 1, 2009
Last Verified:	November 2009

Keywords provided by Pharmaxis:


bronchial hyperresponsiveness

Additional relevant MeSH terms:


Asthma Bronchial Hyperreactivity Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Methacholine Chloride Mannitol Miotics Autonomic Agents	Peripheral Nervous System Agents Physiological Effects of Drugs Parasympathomimetics Bronchoconstrictor Agents Respiratory System Agents Muscarinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Diuretics, Osmotic Diuretics Natriuretic Agents

To Top